Zeneca suffers 8% fall in share price
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.ASTRAZENECA, the Anglo- Swedish drugs company, suffered an 8 per cent fall in its share price yesterday, wiping pounds 4bn from its market value, as a long-awaited research and development symposium failed to provide news to offset a general sell-off of pharmaceutical stocks.
Attention focused on fresh data on esomeprazole, a successor to Losec, the antiulcerant that is its lead product facing patent expiry. The group said the new drug, to be marketed under the brand name of Nexium, had been filed with the US Food and Drug Administration. However, analysts were left wanting more.
"The data didn't support the idea that Nexium would be a substantially better product than Losec, as the market had been led to believe," said one analyst.
"Nexium has got to blow people's socks off, but the case for it is still inconclusive," said Paul Diggle, analyst at SG Securities.
AstraZeneca said Nexium was as effective in four weeks as Losec in eight. Losec, the world's most prescribed antiulcerant, comes off patent in the United States in 2001.
AstraZeneca has had mixed success in seeking patent extensions in countries where Losec's patent has already expired.
However, bullish statements on other products helped limit the damage to the shares inflicted on by downgrades to the sector by brokers concerned that US healthcare budgets would be slashed in 2000.
The company said it intended to be the world leader in all areas of cardiovascular, gastrointestinal, cancer and pain control treatments by 2010.
ZD4522, a so-called "superstatin" for lowering cholesterol levels, showed signs in trials of being more efficacious than the present class leader. The group said it had commenced final-stage trials on an oral thrombosis treatment, the first real advance in the field in 50 years.
The group said it aimed to double the value of its drugs portfolio within five years. Dr Claes Wilhelmsson, AstraZeneca's R&D director, said: "These are challenging targets. This company demands nothing less. I am confident we can exceed expectations in future."
Investment, page 21
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments